Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls
Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls
复制标题
晚期非小细胞肺癌患者与对照组血清M30和M65值的比较
DOI：
--
复制
发表时间：
2012
影响因子：
3.4
通讯作者：
M. Gumus
中科院分区：
文献类型：
--
作者：
B. Oven Ustaalioglu;A. Bilici;Ş. Ercan;A. Orçun;M. Seker;A. Ozkan;Recep Ustaalioğlu;M. Gumus
研究背景M30和M65是细胞角蛋白18的衍生物，在细胞死亡过程中从上皮细胞释放。这些标记物可用于评估几种肿瘤的预后和化疗反应。本文对32例晚期非小细胞肺癌（NSCLC）患者和32例健康人血清M30和M65进行了检测。ELISA定量法测定血清M30和M65值。采用ROC分析确定血清M65的最佳临界值，并进行单因素分析，以确定M65值在预测无进展生存期（PFS）中的重要性。结果患者组和对照组的血清M30值无显著性差异（445.44±536.17 vs.340.56 ±345.07，p=1）。发现患者的平均血清M65值显著高于健康对照（1421.30±1662.59 vs.648.85 ±341.17，p<0.001）。血清M65预测PFS的最佳截断值为1311.64 U/l（AUC 0.58，敏感性和特异性分别为45.5%和85.7%）。血清M65值≥1311.64 U/l的患者的PFS比血清M65值<1311.64 U/l的患者差，p=0.01）。血清M30值与患者组PFS之间无相关性（p=0.4）。结论血清M65值在晚期NSCLC患者中升高，血清M65水平升高可预测患者的PFS。
BackgroundM30 and M65 are derivatives of cytokeratin 18 and released from the epithelial cell during cell death. These markers can be used to evaluate prognosis and chemotherapy response in several tumours. We evaluated serum M30 and M65 values in patients with advanced non-small-cell lung cancer (NSCLC) compared with those in a healthy group.Material and methodsThirty-two patients with advanced NSCLC and thirty-two healthy people were included in the study. Serum M30 and M65 values were measured by quantitative ELISA method. The best cut-off value for serum M65 was calculated by ROC analysis and then univariate analysis was performed to determine the importance of M65 value in predicting progression-free survival (PFS).ResultsThere were no differences between mean serum M30 values between patients and controls (445.44±536.17 vs. 340.56±345.07, p=1). The mean serum M65 values were found to be significantly higher in patients than in healthy controls (1421.30±1662.59 vs. 648.85±341.17, p<0.001). The best cut-off value for serum M65 predicting PFS was 1311.64 U/l (AUC 0.58, sensitivity and specificity were 45.5% and 85.7% respectively). The patients with serum M65 values ≥1311.64 U/l had worse PFS than patients with serum M65 values <1311.64 U/l, p=0.01). There was no correlation between serum M30 value and PFS in the patient group (p=0.4).ConclusionsOur results indicated that serum M65 values elevated in advanced NSCLC compared to a healthy control group and elevated serum M65 level can predict PFS in patients.